On this episode of Stock Movers:
- NatWest raised its guidance for the year after beating estimates in the 3Q, delivering its highest earnings in at least a decade.
- Sanofi’s profit rose more than analysts expected last quarter, lifted by demand for its blockbuster skin and asthma drug Dupixent.
- Saab boosted its organic revenue forecast for the full year, benefiting from the uncertainty of the geopolitical landscape, adding it's received a record high order backlog.
See omnystudio.com/listener for privacy information.
